The briefing
The FDA has approved Moderna’s mFlusiva, the first mRNA-based influenza vaccine, following positive Phase III results. The decision marks a milestone for mRNA platforms beyond COVID-19 and could reshape seasonal flu immunization.
Original headline
FDA Approves First mRNA Flu Vaccine